Shilpa Medicare Ltd. (SHILPAMED) fundamentals
Shilpa Medicare Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SHILPAMED (ISIN INE790G01031). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Shilpa Medicare Ltd. does
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
Valuation and market data
| Last close | ₹961.15 |
|---|---|
| Market capitalisation | ₹18,800 crore |
| Enterprise value | ₹19,022 crore |
| P/E (TTM) | 77.26 |
| Price to book | 7.26 |
| Price to sales (TTM) | 6.74 |
| Book value per share | ₹132.47 |
| Dividend yield | 16.65% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Dec 03 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹635 crore | ₹148 crore | ₹133 crore | 6.80 |
| Mar 2025 | ₹547 crore | ₹105 crore | ₹68 crore | 3.48 |
| Mar 2024 | ₹399 crore | ₹38 crore | ₹27 crore | 3.10 |
| Mar 2023 | ₹316 crore | ₹-58 crore | ₹-49 crore | 6.59 |
| Mar 2022 | ₹398 crore | ₹27 crore | ₹20 crore | 16.87 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 40.1% |
|---|---|
| Foreign institutions (FII) | 11.4% |
| Mutual funds | 4.2% |
| Other domestic institutions | 3.8% |
| Retail and others | 40.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.